WASHINGTON — It’s less than a week old, but a shadowy new pharma advocacy group is already launching diatribes against advocates for lower drug prices, blasting pharmacy middlemen and defending even sky-high list prices for prescription drugs.
The new group, the Alliance to Protect Medical Innovation, says its goal is to “help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry.” An “About Us” section on its website describes it as a 501(c)(4) nonprofit.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
